Enanta Opens $75M ATM Days After Pfizer Patent Defeat
Capital Build
Company Background
Enanta Pharmaceuticals is a Watertown, Massachusetts clinical-stage biotech focused on small-molecule antivirals and immunology drugs. Its only commercial-stage revenue is a royalty on AbbVie's hepatitis C regimen MAVYRET/MAVIRET — the product contains glecaprevir, a protease inhibitor Enanta discovered. Revenue has run roughly $15–$19 million per quarter, but 54.5% of each royalty payment is forwarded to OMERS, a Canadian pension fund, through June 2032 under a 2023 royalty monetization deal that raised $200 million upfront.
The company's active development program centers on zelicapavir, an RSV N-protein inhibitor that produced positive Phase 2b data in high-risk adult outpatients in September 2025 — reducing time to full symptom resolution by 6.7 days in the target HR3 population and cutting RSV-related hospitalizations to zero versus 5% on placebo. In parallel, Enanta has three early-stage immunology programs targeting KIT, STAT6, and MRGPRX2.
Net losses have improved sharply: the fiscal year ended September 30, 2025 produced an $81.9 million loss, roughly 30% narrower than the prior year's $116 million. The trend has continued into fiscal 2026, with net losses of $11.9 million in Q1 and $13.1 million in Q2. Cash and marketable securities stood at $227 million at March 31, 2026, and management guided in May 2026 that this position — augmented by the retained portion of future AbbVie royalties — would fund operations into fiscal 2029.
What Was Disclosed
Enanta entered into an Open Market Sale Agreement with Jefferies LLC on July 2, 2026, establishing an at-the-market equity program under which it may sell up to $75 million of common stock at prevailing market prices on Nasdaq. Jefferies will receive a commission of up to 3.0% of the gross sales price on each share sold. Enanta retains full discretion over whether, when, and how much to sell — the agreement carries no obligation to draw on the facility.
The shares are being offered off a shelf registration statement filed February 11, 2026 and declared effective by the SEC on February 20, 2026 — months before the recent patent and clinical-program developments. A prospectus supplement dated July 2, 2026 designates up to $75 million as the ATM tranche. The agreement may be terminated by either party in accordance with its terms.
Why It Matters
The ATM arrived nine days after the Federal Circuit affirmed, on June 23, 2026, that the claims of Enanta's U.S. Patent No. 11,358,953 — its domestic attempt to collect infringement damages from Pfizer over Paxlovid — were invalid. That ruling extinguishes a speculative litigation upside but carries no cash consequence for the company's operating financials: the HCV royalties from AbbVie that underpin Enanta's revenue and cash-runway guidance flow from a separate commercial agreement and are wholly unaffected by the Pfizer outcome.
The more material driver of the ATM is likely the spending trajectory ahead. On June 18, 2026 — two weeks before the ATM — Enanta announced it would initiate a registrational Phase 2b/3 zelicapavir trial in high-risk adults in Q4 2026 and a pediatric Phase 2b trial in Q3 2026, with topline data from both expected in 2027. Registrational trials in this patient population — targeting a minimum of 860 patients across the adult study — will meaningfully increase R&D costs relative to the recent run-rate. The ATM gives management a low-friction mechanism to raise incremental capital if spending accelerates before the trials produce data.
Enanta has done this before: in October 2025, it raised $74.8 million gross in an underwritten public offering at $10.00 per share, timed shortly after reporting positive Phase 2b topline data. The new ATM, by contrast, is opportunistic rather than structured — Enanta may sell nothing at all. With $227 million on hand at March 31, 2026 and a quarterly burn rate that has fallen to the low-teens of millions, the company is not pressing for immediate capital. The facility is better read as a buffer against the cost uncertainty of a global registrational program than as evidence of a near-term funding gap. A UPC hearing in the European Pfizer patent case is scheduled for September 29, 2026, preserving some residual upside on the litigation front.